Sundry Photography/iStock Editorial via Getty Images Merck ( NYSE: MRK ) has received FDA approval for its Capvaxive 21-valent conjugate vaccine for the prevention of pneumonia in adults. The drugmaker said the vaccine is designed to cover serotypes responsible for around 84% of invasive pneumococcal disease in people aged 50 years and older. An advisory committee of the US Centers for Disease Control and Prevention is expected to meet later this month to discuss recommendations for use of the vaccine in adults.
Capvaxive will likely compete against Pfizer's ( PFE ) top-selling pneumonia vaccine, Prevnar 20. More on Merck Merck & Co., Inc.
(MRK) Goldman Sachs 45th Annual Global Healthcare Conference - (Transcript) Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Transcript) Merck's Keytruda gains approval for additional endometrial carcinoma indication Merck shares traded in the green for seven straight days.
